Table 3 The treatment of psychiatric symptoms in patients with Parkinson’s disease by the composite neurologist population
From: Managing non-motor symptoms of Parkinson disease in China: clinical perspectives
Item | Total | Specialty | Have or have not read the guideline | ||||
|---|---|---|---|---|---|---|---|
Movement disorder Specialists (n = 259) | General neurologists (n = 595) | p value | Read (n = 693) | Not read (n = 161) | p value | ||
Depression/anxiety | |||||||
Dopamine agonists, n(%) | 283(33.1) | 124(47.9) | 159(26.7) | < 0.001 | 248(35.8) | 35(21.7) | 0.001 |
SNRIs, n(%) | 123(14.4) | 38(14.7) | 85(14.3) | 0.883 | 104(15.0) | 19(11.8) | 0.297 |
SSRIs, n(%) | 326(38.1) | 75(29.0) | 251(42.2) | < 0.001 | 268(38.7) | 58(36.0) | 0.533 |
NaSSAs, n(%) | 31(3.6) | 9(3.5) | 22(3.7) | 0.873 | 29(4.2) | 2(1.2) | 0.072 |
Benzodiazepines, n(%) | 13(1.5) | 0(0) | 13(2.2) | 0.036 | 8(1.2) | 5(3.1) | 0.069 |
Traditional Chinese medicine, n(%) | 14(1.6) | 6(2.3) | 8(1.3) | 0.462 | 12(1.7) | 2(1.2) | 0.660 |
rTMS, n(%) | 270(31.6) | 108(41.7) | 162(27.2) | < 0.001 | 240(34.6) | 30(18.6) | < 0.001 |
MECT, n(%) | 32(3.7) | 15(5.8) | 17(2.9) | 0.038 | 26(3.8) | 6(3.7) | 0.988 |
Cognitive impairment and dementia | |||||||
AchEIs, n(%) | 716(83.9) | 232(89.6) | 484(81.3) | 0.003 | 613(88.5) | 103(64.0) | < 0.001 |
Memantine, n(%) | 456(53.4) | 155(59.9) | 301(50.6) | 0.013 | 394(56.9) | 62(38.5) | < 0.001 |
Ginkgo biloba extract, n(%) | 376(44.3) | 140(54.1) | 236(39.7) | < 0.001 | 316(45.6) | 60(37.3) | 0.055 |
Citicoline, n(%) | 360(42.2) | 116(44.8) | 244(41.0) | 0.304 | 306(44.2) | 54(33.5) | 0.014 |
Chinese patent medicine, n(%) | 181(21.2) | 68(26.2) | 113(19.0) | 0.017 | 155(22.4) | 26(16.2) | 0.082 |
Psychosis | |||||||
quetiapine, n(%) | 456(53.4) | 195(75.3) | 261(43.9) | < 0.001 | 397(57.3) | 59(36.7) | < 0.001 |
Olanzapine, n(%) | 417(48.8) | 102(39.4) | 305(51.3) | 0.001 | 334(48.2) | 73(45.3) | 0.514 |
Clozapine, n(%) | 295(34.5) | 145(56.0) | 150(25.2) | < 0.001 | 273(39.4) | 22(13.7) | < 0.001 |
aripiprazole, n(%) | 49(5.7) | 16(6.2) | 33(5.6) | 0.715 | 49(7.1) | 9(5.6) | 0.929 |
Risperidone, n(%) | 172(20.1) | 54(20.9) | 118(19.8) | 0.733 | 149(21.5) | 23(14.3) | 0.04 |